Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

82 Gleizes, P. E., J. S. Munger, I. Nunes,
J. G. Harpel, R. Mazzieri, I. Noguera
and D. B. Rifkin. 1997. TGF-b latency:
biological significance and mechanisms
of activation. Stem Cells 15: 190.
83 Koli, K., J. Saharinen, M. Hyytiainen,
C. CP and J. Keski-Oja. 2001. Latency,
activation and binding proteins
of TGF-b. Microsc. Res. Tech. 52: 354.
84 Dubois, C. M., F. Blanchette,
M. H. Laprise, R. Leduc, F. Grondin
and N. G. Seidah. 2001. Evidence that
furin is an authentic transforming
growth factor-b1-converting enzyme.
Am. J. Pathol. 158: 305.
85 Chu, T. M. and E. Kawinski. 1998.
Plasmin, substilisin-like endoproteases,
tissue plasminogen activator and urokinase
plasminogen activator are involved
in activation of latent TGF-b1 in human
seminal plasma. Biochem. Biophys. Res.
Commun. 253: 128.
86 Nunes, I., P. E. Gleizes, C. N. Metz
and D. B. Rifkin. 1997. Latent transforming
growth factor-b binding protein
domains involved in activation and
transglutaminase-dependent cross-linking
of latent transforming growth factor-b.
J. Cell Biol. 136: 1151.
87 Nunes, I., R. L. Shapiro and D. B. Rifkin.
1995. Characterization of latent
TGF-b activation by murine peritoneal
macrophages. J. Immunol. 155: 1450.
88 Crawford, S. E.,V. Stellmach,
J. E. Murphy-Ullrich, S. M. Ribeiro,
J. Lawler, R. O. Hynes, G. P. Boivin
and N. Bouck. 1998. Thrombospondin-
1 is a major activator of TGF-b1 in vivo.
Cell 93: 1159.
89 Ribeiro, S. M., M. Poczatek,
S. Schultz-Cherry, M. Villain and
J. E. Murphy-Ullrich. 1999. The activation
sequence of thrombospondin-1
interacts with the latency-associated
peptide to regulate activation of latent
transforming growth factor-b. J. Biol
Chem. 274: 13586.
90 Sasaki, A., H. Naganuma, E. Satoh,
T. Kawataki, K. Amagasaki and H. Nukui.
2001. Participation of thrombospondin-1
in the activation of latent
transforming growth factor-b in malignant
glioma cells. Neurol. Med. Chir (Tokyo)
41: 253.
References
91 Harpel, J. G., S. Schultz-Cherry,
J. E. Murphy-Ullrich and D. B. Rifkin.
2001. Tamoxifen and estrogen effects
on TGF-b formation: role of
thrombospondin-1, avb3 and integrinassociated
protein. Biochem. Biophys.
Res. Commun. 284: 11.
92 Yang, L., E. E. Tredget and A. Ghahary.
2000. Activation of latent transforming
growth factor-b1 is induced by
mannose 6-phosphate/insulin-like
growth factor-II receptor. Wound Repair
Regen. 8: 538.
93 Dubois, C. M., M. H. Laprise,
F. Blanchette, L. E. Gentry and R. Leduc.
1995. Processing of transforming
growth factor b1 precursor by human
furin convertase. J. Biol. Chem. 270:
10618.
94 Leitlein, J., S. Aulwurm, R. Waltereit,
U. Naumann, B. Wagenknecht,
W. Garten, M. Weller and M. Platten.
2001. Processing of immunosuppressive
pro-TGF-b1, 2 by human glioblastoma
cells involves cytoplasmic and
secreted furin-like proteases. J. Immunol.
166: 7238.
95 Zujewski, J., A. Vaughn-Cooke,
K. C. Flanders, M. A. Eckhaus,
R. A. Lubet and L. M. Wakefield.
2001. Transforming growth factors-b
are not good biomarkers of chemopreventive
efficacy in a preclinical breast
cancer model system. Breast Cancer Res.
3: 66.
96 Hashimoto, K.,Y. Nio, S. Sumi,
T. Toga, H. Omori, M. Itakura and
S. Yano. 2001. Correlation between
TGF-b1 and p21 (WAF1/CIP1) expression
and prognosis in resectable invasive
ductal carcinoma of the pancreas.
Pancreas 22: 341.
97 Pierce, D. F., Jr, A. E. Gorska, A. Chytil,
K. S. Meise, D. L. Page, R. J. Coffey,
Jr and H. L. Moses. 1995. Mammary
tumor suppression by transforming
growth factor b1 transgene expression.
Proc. Natl Acad. Sci. USA 92:
4254.
98 Ashley, D. M., F. M. Kong, D. D. Bigner
and L. P. Hale. 1998. Endogenous
expression of transforming growth factor
b1 inhibits growth and tumorigenicity
and enhances Fas-mediated apopto-
141